Pharmaceuticals, Biotechnology and Life Sciences
The updated data from Clovis’s TRITON2 trial confirm the potential role of rucaparib in treating metastatic castration-resistant prostate cancer
Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Exploratory…
Quality-adjusted progression free survival (QA-PFS) andquality-adjusted time without cancer related symptoms or toxicity(Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment overplacebo from a patient perspective
Exploratory analyses of ARIEL3 Rubraca data in recurrent ovarian cancer presented in oral plenary and poster sessions Maintenance treatment with…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to orphan drug Rubraca (rucaparib) to treat women with…